Tesamorelin (10mg)
$119.99
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the full 44-amino-acid GHRH sequence modified with a trans-3-hexenoic acid conjugation to improve metabolic stability. In research settings, Tesamorelin is studied for its interactions with pituitary GHRH receptors, growth hormone secretion dynamics, and downstream IGF-1 axis signaling.
BioRhex supplies Tesamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- COA-verified
- In stock
- ≥99% purity.
- USA manufactured.
What Is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the full 44-amino-acid GHRH sequence modified with a trans-3-hexenoic acid conjugation to improve metabolic stability. In research settings, Tesamorelin is studied for its interactions with pituitary GHRH receptors, growth hormone secretion dynamics, and downstream IGF-1 axis signaling.
BioRhex supplies Tesamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Compound Overview
Tesamorelin is a stabilized GHRH analogue studied for its hypothalamic-pituitary GH axis interactions. Preclinical and in vitro research models examine how Tesamorelin may influence:
• GHRH receptor binding and pituitary somatotroph activation
• Pulsatile GH secretion pattern modeling
• IGF-1 axis downstream signaling dynamics
• Lipid metabolic pathway interactions in experimental models
• GH axis pharmacology relative to native GHRH
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.
History of Tesamorelin
Tesamorelin was developed as a stabilized GHRH analogue to address the short half-life of native GHRH in biological systems. The trans-3-hexenoic acid modification significantly increases resistance to dipeptidyl peptidase degradation, extending the compound’s useful activity window in research models.
Research into Tesamorelin’s GH axis interactions established it as a useful tool for studying GHRH receptor pharmacology and pituitary somatotroph biology in controlled experimental settings.
Tesamorelin remains an active reference compound in GH axis research, with interest expanding into its downstream metabolic signaling interactions in preclinical models.
Molecular Structure
Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
Research Findings
Published and preclinical research on Tesamorelin covers several areas of scientific investigation, including:
GHRH receptor pharmacology: Studies examine Tesamorelin’s receptor binding kinetics and downstream cAMP signaling in pituitary somatotroph cell models.
GH secretion dynamics: Research investigates pulsatile GH release patterns associated with GHRH receptor activation in experimental systems.
IGF-1 axis research: Laboratory models evaluate downstream IGF-1 production and signaling in response to Tesamorelin-induced GH axis modulation.
Metabolic pathway interaction: Studies explore connections between GH axis activity and lipid metabolic signaling in preclinical environments.
All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.
References
FAQ
What type of research is Tesamorelin used for?
What type of research is Tesamorelin used for?
Tesamorelin is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.
Where is BioRhex’s Tesamorelin manufactured?
Where is BioRhex’s Tesamorelin manufactured?
All BioRhex compounds, including Tesamorelin, are manufactured in a GMP-compliant facility located in the United States.
What testing does BioRhex conduct on Tesamorelin?
What testing does BioRhex conduct on Tesamorelin?
Every batch of Tesamorelin undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.
Is Tesamorelin approved for human use?
Is Tesamorelin approved for human use?
No. Tesamorelin is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.
Who should handle this compound?
Who should handle this compound?
Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.
Research Use Only
All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. Tesamorelin is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.
RELATED PRODUCTS
AOD9604 (5mg)
BPC-157
BPC-157 + TB-500
CJC (no DAC) + Ipamorelin (10mg)
